Healthpeak Is Buying Vacancy Nobody Else Wants — And the Tape Won't Pay For It
A third guidance raise, life science occupancy up 270bps year to date, and a stock 14% off its July high. The market is pricing the 2027 refinancing wall, not the lease-up.
DOC · Earnings Call · 2026-11-03
Three raises, one sagging stock
Healthpeak lifted FFO guidance for the third time this year — up $0.02 at the midpoint to $1.76–$1.78 — and raised total same-store guidance 50bps, lab from down 4.5% to down 3%–6%, and senior housing 250bps to 16%–19%. The shares are down 10.6% over 90 days and 14.3% below the July 28 peak of $22.82. That gap is the entire story of this report. The reason sits in the fourth quarter. Implied Q4 FFO of $0.42 annualizes to $1.68 — *below* the midpoint of the year just guided. Two analysts asked about it and CFO Kelvin Moses declined the bridge, instead pointing at $1.4 billion of 2027 maturities: “our cost of borrowing that's maturing is around 3%, and that's certainly much lower than where the market is today.” — Kelvin Moses, Chief Financial Officer (CFO) · 2026-11-03 He is not bluffing. Interest expense has compounded 111% over three years to $92 million a quarter, up 23% year over year, and management has already pre-funded with $900 million of delayed-draw term loans at SOFR + 80bps because, as Moses put it, that pricing is inside where bonds could be issued today. Strip the rates out and the operating story is genuinely good. Outpatient is throwing off cash releasing spreads running above historical averages at leasing costs of just 9.5% of rents; lab has delivered positive net absorption three quarters running.Buying vacancy on purpose
Lab occupancy rose 130bps sequentially to 79.8% — 270bps since January — against a February promise of 100bps that Scott Brinker concedes "was not a consensus view at the time." Torrey Pines is now fully leased versus a submarket that sat at 65% six months ago, and lease executions hit 480,000 square feet, the strongest quarter in over a year, with another 643,000 square feet of executions and LOIs signed since quarter-end. The new activity is on the buy side. Three acquisitions at 41% current occupancy, a 5% in-place yield, and 9%–10% underwritten at stabilization — plus roughly $1 billion of closed-or-pipeline deals, funded from nearly $2 billion of outpatient sales, recaps and loan repayments at a blended 6% cap rate. The logic is ecosystem density, not asset count: “Usually when you are buying assets, you get one but not the other. If it is strategic, it is usually expensive. If it is cheap, it is usually not strategic.” — Scott Brinker, Chief Executive Officer (CEO) · 2026-11-03 The keyword map confirms this is a genuine shift, not boilerplate. Acquired vacancy enters Healthpeak's top-30 for the first time, ranking high, alongside lease execution and Torrey Pines. The older vocabulary was defensive — watch lists, bad debt, tenants trying to raise capital. That language has essentially vanished. Moses now cites $150 billion of biotech capital formation and says the tenant credit profile "has meaningfully improved." Why no competition? Brinker is blunt: “It's still kind of a bad word, life science, in most real estate shops around the country.” — Scott Brinker, Chief Executive Officer (CEO) · 2026-11-03 He also insisted Healthpeak has not retraded a single deal despite rate volatility that has other buyers pausing — a deliberate contrast with the market. The incremental demand story has a new leg: AI and robotics tenants taking shell space at lower TIs. Life science specialist Scott Bohn says the pipeline is still over 75% biotech but that “there is purely incremental demand from that” — Scott Bohn, Executive (likely SVP/Head of Life Science or similar, based on context) · 2026-11-03 — power, floor loads and ceiling heights make lab shells attractive to adjacent users. This is the same physical AI thread showing up across the global reporter set — lab-adjacent real estate quietly becoming AI infrastructure.The metric the CEO refuses to run the company by
This is the third consecutive call where Brinker has attacked same-store NOI, and it is no longer a throwaway. In August he said “Same-store is really a terrible metric.” — Scott Brinker, President and Chief Executive Officer · 2026-05-06 In May he was already calling it "less relevant." This quarter he escalated to a full doctrine — that TIs and asset churn let management manufacture a releasing spread and a retention rate without moving bottom-line cash.Investors should treat the repetition as a tell, not a novelty. It is what a management team says when a headline number is about to look worse than the business — the 41%-occupied acquisitions will mechanically reset reported lab occupancy lower. The counter-evidence is that the operating metrics he prefers are inflecting: total occupancy high-70s in October 2025, 79.8% lab now, outflow of 90.3% in outpatient, and — new this quarter — “We've had even a few situations in recent months where we have multiple tenants bidding for the same suite or building, which we haven't seen in many years.” — Scott Brinker, Chief Executive Officer (CEO) · 2026-11-03 That is an actual pricing-power signal, and it is the one thing the same-store debate cannot capture.I've always felt like this whole concept of moving stuff in and out of the pool is just very misleading. I understand why same store became a metric that the real estate community monitored, but I just think it's been abused.